Navigation Links
SureClinical Completes FDA 21 CFR Part 11 Compliance Audit of SureTrial® eTMF Cloud Edition
Date:8/1/2013

Rancho Cordova, CA (PRWEB) August 01, 2013

SureClinical, a provider of cloud-based content management application software and services for health sciences, announced today that it has successfully completed an FDA 21 CFR Part 11 compliance audit of its SureTrial® eTMF clinical trials content management application. More information is available at http://www.SureTrial.com.

Conducted through a leading independent GxP process auditing organization, SureTrial’s successful audit will help sponsors, clinical research organizations, academic research organizations and investigator sites running clinical trials comply with FDA rules and regulations related to electronic records and electronic signatures used in Electronic Trial Master File, or eTMF implementations.

“SureTrial eTMF is the first eTMF cloud software solution that completely addresses FDA 21 CFR Part 11 regulations and that has successfully completed an independent audit and validation,” said Zack Schmidt, President and CEO of SureClinical. “With the independent audit and validation of SureTrial eTMF, life sciences organizations can accelerate their compliance and validation initiatives for faster application deployment, insuring higher levels of GxP process management with eTMF documents and medical images.”

The FDA 21 CFR Part 11 compliance audit was performed by a leading independent GxP process organization that provides training to industry and US FDA regulatory agency personnel on 21 CFR Part 11 regulated computerized systems. The audit covered requirements for electronic records and electronic signatures under 21 CFR Part 11.

About SureClinical

SureClinical is a provider of cloud-based content management application software for health sciences. Headquartered in the Northern California, SureClinical’s founders have proven expertise in delivering market leading enterprise applications in the health sciences and enterprise mobile computing areas. To find out more, visit http://www.SureClinical.com.

###

Trademarks
SureClinical, SureTrial®, SureTrial® eTMF are trademarks of SureClinical.

Copyright © 2013 SureClinical. All rights reserved. SureClinical, SureTrial eTMF and the SureTrial logo are trademarks of SureClinical. Other names used herein may be trademarks of their respective owners.

http://www.SureClinical.com
http://www.SureTrial.com

Read the full story at http://www.prweb.com/releases/2013/8/prweb10982140.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
2. InnoPharma Completes $15 Million Series A Financing
3. Aratana Therapeutics Completes $15 Million Series B Financing
4. CeNeRx BioPharma Completes $4.85 Million Financing
5. PDL BioPharma Completes Regular Quarterly Dividend Payment
6. MiMedx Group Completes $5,000,000 Private Placement
7. goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit
8. Auxogyn Completes $20 Million In Series A Funding
9. CitiusTech Completes Another Milestone Year: Revenues Grow by 59% in 2011
10. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
11. Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... and BEIJING , Nov. 30, ... commercial provider of genomic services and solutions with cutting ... that it has completed a USD $75 Million [515 ... Co., Ltd.,s CMB International Capital Management ( Shenzhen ... Management Co., Ltd. ("SDIC Innovation") and Shanghai Sigma Square ...
(Date:11/30/2016)... Mass. , Nov. 30, 2016   Merck ... that it has entered into a set of agreements ... services for Merck,s collection of genetic reagents such as ... with Evotec,s screening expertise offers an accelerated pathway to ... discovery starts with the identification of new targets, a ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... development of a new orally administered treatment for Alzheimer’s disease (AD), today announced ... a Phase 2a clinical trial of T3D-959 in mild to moderate Alzheimer’s patients ...
(Date:11/30/2016)... ... 2016 , ... ProMIS Neurosciences (“ProMIS” or the “Company”), a ... announced that all five of its validated monoclonal antibody (mAb) therapeutic candidates for ... forms of Amyloid beta (Aß) in vitro. , “We previously demonstrated that the ...
Breaking Biology Technology:
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
Breaking Biology News(10 mins):